<DOC>
	<DOCNO>NCT02334306</DOCNO>
	<brief_summary>A Phase 2a study evaluate efficacy safety AMG 557/MEDI5872 Primary Sjögren 's Syndrome</brief_summary>
	<brief_title>A Phase 2a , Randomized , Placebo Controlled , Study Evaluate Safety Efficacy AMG 557/MEDI5872 Primary Sjögren 's Syndrome</brief_title>
	<detailed_description>This Phase 2a , multicenter , randomize , double-blind , placebo-controlled , parallel-group study evaluate clinical biologic efficacy , well safety SC dose AMG 557/MEDI5872 adult subject Primary Sjögren 's Syndrome .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Sjogren 's Syndrome</mesh_term>
	<criteria>Age 18 75 year time sign ICF . Fulfill AmericanEuropean Consensus Group ( AECG ) criteria pSS ESSDAI score ≥ 6 . Positive antiSSA and/or antiSSB autoantibody least IgG &gt; 13 g/L RF level &gt; upper limit normal ( ULN ) positive test cryoglobulins Willingness undergo protocolrequired minor salivary gland biopsy . Negative TB test screen Immunization date determine local standard care . Previous treatment AMG 557/MEDI5872 . Evidence sign symptom viral , bacterial , fungal infection within 2 week ( 14 day ) prior randomization ( Day 1 ) accord assessment investigator ; infection require IV antibiotic antiviral treatment within 8 week randomization ( Day 1 ) ; history herpes zoster within 3 month prior randomization ( Day 1 ) . Evidence significant renal insufficiency Positive test screen hepatitis B , hepatitis C , human immunodeficiency virus ( HIV ) antibody . Prior administration follow : 1 . Belimumab past 6 month prior randomization ( Day 1 ) ; 2 . Rituximab past 12 month CD19+ B cell &lt; 5/µL rituximab treatment 12 month prior randomization ( Day 1 ) ; 3 . Abatacept past 6 month prior randomization ( Day 1 ) ; 4 . Tumor necrosis factor inhibitor ( adalimumab , certolizumab , etanercept , golimumab , infliximab ) past 3 month prior randomization ( Day 1 ) ; 5 . Tocilizumab past 3 month prior randomization ( Day 1 ) ; 6 . Cyclophosphamide ( alkylating agent ) past 6 month prior randomization ( Day 1 ) ; cyclosporine ( except eye drop ) , tacrolimus , sirolimus , mycophenolate mofetil , azathioprine , leflunomide past 3 month prior randomization ( Day 1 ) . Receiving follow : 1 . Corticosteroids : &gt; 10 mg/day oral prednisone ( equivalent ) ; Any change initiation new dose within 4 week prior sign ICF randomization ( Day 1 ) ; Intramuscular , IV , intraarticular corticosteroid within 4 week prior sign ICF randomization ( Day 1 ) ; Any change initiation new dose topical corticosteroid within 2 week prior sign ICF randomization ( Day 1 ) ; 2 . Antimalarials : increase initiation new dose antimalarial ( eg , chloroquine , hydroxychloroquine , quinacrine ) within 12 week prior sign ICF randomization ( Day 1 ) . 3 . Methotrexate : &gt; 20 mg/week methotrexate ; Any change initiation new dose methotrexate within 4 week prior sign ICF randomization ( Day 1 ) ; Any change route administration . 4 . Any increase initiation new dose regularly schedule nonsteroidal anti inflammatory drug ( NSAIDs ) within 2 week prior sign ICF randomization ( Day 1 ) . 5 . Cevimeline pilocarpine cyclosporine eye drop ( Restasis ) : increase initiation new dos within 2 week prior sign ICF randomization ( Day 1 ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>